 |
BioWorld-Insight-2010-02-01
Endpoint Hit, Stock Walloped: Street, Media Miss the Point?
U.S. Public Offering Performance of Biotech Industry by Underwriter: January 1 - December 31, 2009*
No Abstract
Endpoint Hit, Stock Walloped: Street, Media Miss the Point?
Last week, Wall Street slammed Poniard Pharmaceuticals Inc. after the company disclosed apparently good news: an endpoint met in the Phase II trial with picoplatin in metastatic colorectal cancer. It was anything but the first time that the wider world reflexively failed - at least from the company's point of view - to understand and appreciate study data.